Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe

Lancet Reg Health Eur. 2025 Feb 19:50:101215. doi: 10.1016/j.lanepe.2025.101215. eCollection 2025 Mar.

Anthony Turpin^{1

2}, Tian V Tian³, Alice Boilève^{4

5

6}, Cindy Neuzillet^{7

8

9}

¹ CHU Lille, University of Lille, Medical Oncology Department, 59000, Lille, France.
² CNRS INSERM UMR9020-U1277, CANTHER Cancer Heterogeneity Plasticity and Resistance to Therapies, Université de Lille, Lille, France.
³ Upper GI and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain.
⁴ Gustave Roussy, Département de Médecine, 94800, Villejuif, France.
⁵ INSERM U1279, Gustave Roussy, 94800, Villejuif, France.
⁶ Université Paris Saclay, 91471, Orsay, France.
⁷ Gastrointestinal Oncology, Medical Oncology Department, Institut Curie, Université Versailles Saint-Quentin-Université Paris-Saclay, Saint-Cloud, France.
⁸ Hepato-Gastroenterology Department, Ambroise Pare University Hospital, APHP, Boulogne-Billancourt, France.
⁹ Molecular Oncology, PSL Research University, CNRS, UMR 144, Institut Curie, Paris, France.

No abstract available